Proteinuric Renal Disease

• CLINICAL_TRIALS research · 2026-02-27
  Clinical Trial Update: Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria [Phase 1]

  Phase 1 trial evaluating sparsentan for proteinuria associated with VEGF signaling pathway inhibitors; status is not yet recruiting.

• CLINICAL_TRIALS withdrawal · 2015-12-28
  Clinical Trial Update: A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease [NA]

  The clinical trial evaluating oral paricalcitol for proteinuric renal disease has been withdrawn. The study record lists Winthrop University…